Sequence variations of Epstein–Barr virus LMP1 gene in gastric cancer and chronic gastritis isolates from Iranian patients EBV LMP1 variations in GC and chronic gastritis patients
Gastroenterology and Hepatology from Bed to Bench,
Aim: The aim of this study was to investigate sequence variations in the C-terminus of latent membrane protein 1 (LMP1) in Epstein-Barr virus (EBV) isolates from Iranian patients with chronic gastritis or gastric cancer (GC).
Background: EBV is an important member of gammaherpesviruses that causes persisting latent human infection. LMP1 is the essential viral oncoprotein that is a key element for B cells immortalization. LMP1 contains of a small twenty-four amino acid cytoplasmic N-terminal region, six transmembrane segments and a two hundred amino acid cytoplasmic C-terminal domain. Most LMP1-mediated signal transduction events are moderated by some functional parts of cytoplasmic C-terminal domain. Sequence variations of LMP1 gene have been described in numerous EBV-isolates.
Methods: This study included 32 EBV positive biopsy tissues from patients with gastric cancer and patients with chronic gastritis. The C-terminal nucleotide sequences of LMP1 were amplified using nested-PCR and analyzed by DNA sequencing.
Results: In the carboxyl-terminal site of patients was observed 4 to 8 copies of the 11 repeat elements (codon 254–302) and there was no relationship between the number of repeat sequences and disease status. The 30-bp deletion corresponding to codon 345–354 of the B95-8 strain was observed in 34% isolates and remaining samples were non-deleted. In group of gastric cancer, a high number of 33-bp repeats (>5 repeats) was observed in 30-bp-deletion (100%) than non-deleted (42%) isolates and the difference was also statistically significant. In addition, the analysis revealed that a gastritis isolate may be result of recombination between Alaskan and China1 strains.
Conclusion: Overall, our results showed no association between the C-terminal sequence variations of LMP1 and malignant or non-malignant isolate origin.
- latent membrane protein 1
- sequence variations
- repeat elements
How to Cite
2. Gequelin LCF, Riediger IN, Nakatani SM, Biondo AW, Bonfim CM. Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant. Revista brasileira de hematologia e hemoterapia. 2011;33(5):383-8.
3. Neparidze N, Lacy J. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Clin Adv Hematol Oncol. 2014;12(6):358-71.
4. Jia X, Guo T, Li Z, Zhang M, Feng Y, Dong B, et al. Clinicopathological and Immunomicroenvironment Characteristics of Epstein–Barr Virus-Associated Gastric Cancer in a Chinese Population. Frontiers in oncology. 2021:3022.
5. Ribeiro J, Oliveira C, Malta M, Sousa H. Epstein–Barr virus gene expression and latency pattern in gastric carcinomas: a systematic review. Future Oncology. 2017;13(6):567-79.
6. Banko A, Miljanovic D, Lazarevic I, Cirkovic A. A Systematic Review of Epstein–Barr Virus Latent Membrane Protein 1 (LMP1) Gene Variants in Nasopharyngeal Carcinoma. Pathogens. 2021;10(8):1057.
7. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Virology. 1999;261(1):79-95.
8. Wang H-Y, Sun L, Li P, Liu W, Zhang Z-G, Luo B. Sequence Variations of Epstein-Barr Virus-Encoded Small Noncoding RNA and Latent Membrane Protein 1 in Hematologic Tumors in Northern China. Intervirology. 2021;64(2):69-80.
9. Ranger-Rogez S. EBV Genome Mutations and Malignant Proliferations. 2020.
10. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. 1993.
11. Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. Journal of general virology. 2006;87(5):1047-74.
12. Neves M, Marinho‐Dias J, Ribeiro J, Sousa H. Epstein–Barr virus strains and variations: Geographic or disease‐specific variants? Journal of medical virology. 2017;89(3):373-87.
13. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. Journal of virology. 2006;80(13):6458-68.
14. Li S-N, Chang Y-S, Liu S-T. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene. 1996;12(10):2129-35.
15. BenAyed-Guerfali D, Ayadi W, Miladi-Abdennadher I, Khabir A, Sellami-Boudawara T, Gargouri A, et al. Characteristics of epstein barr virus variants associated with gastric carcinoma in Southern Tunisia. Virology journal. 2011;8(1):1-9.
16. Chen JN, Ding YG, Feng ZY, Li HG, He D, Du H, et al. Association of distinctive Epstein–Barr virus variants with gastric carcinoma in Guangzhou, southern China. Journal of medical virology. 2010;82(4):658-67.
17. Chen J-n, Jiang Y, Li H-g, Ding Y-g, Fan X-j, Xiao L, et al. Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric carcinoma in gastric remnant carcinoma in Guangzhou, southern China, an endemic area of nasopharyngeal carcinoma. Virus research. 2011;160(1-2):191-9.
18. Cheng N, Hui D-y, Liu Y, Zhang N-n, Jiang Y, Han J, et al. Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms. Gastric Cancer. 2015;18(2):246-55.
19. Ai J, Xie Z, Liu C, Huang Z, Xu J. Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese children. Virology journal. 2012;9(1):1-8.
20. Fukayama M, Ushiku T. Epstein-Barr virus-associated gastric carcinoma. Pathology-Research and Practice. 2011;207(9):529-37.
21. See HS, Yap YY, Yip WK, Seow HF. Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia. World journal of surgical oncology. 2008;6(1):1-10.
22. Huen D, Henderson S, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 1995;10(3):549-60.
23. Moorthy RK, Thorley-Lawson DA. Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. Journal of virology. 1993;67(5):2637-45.
24. Kanai K, Satoh Y, Saiki Y, Ohtani H, Sairenji T. Difference of Epstein–Barr virus isolates from Japanese patients and African Burkitt’s lymphoma cell lines based on the sequence of latent membrane protein 1. Virus genes. 2007;34(1):55-61.
25. Jovanovic T. Analysis of the variability of epstein-barr virus genes in infectious mononucleosis: Investigation of the Potential Correlation with biochemical parameters of hepatic involvement. Journal of Medical Biochemistry. 2016;35(3):337-46.
26. Miller WE, Edwards RH, Walling DM, Raab-Traub N. Sequence variation in the Epstein–Barr virus latent membrane protein 1. Journal of General Virology. 1994;75(10):2729-40.
- Abstract Viewed: 0 times